Royalty Report: Drugs, Diagnostic, Biotechnology – Collection: 1801


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Diagnostic
  • Biotechnology
  • Diagnostic Substances
  • Test/Monitoring

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 1801

License Grant
The University grants to Licensee and its Affiliates an exclusive worldwide license under Patent Rights (5,484,735) relating to Immunoassay Constructs to Quantitate Glucosylated-Hemoglobin and other Glucosylated Serum Proteins (NU 8403).
License Property
'Licensed Products' shall mean diagnostic assays for determining hemoglobin type A1c.
Field of Use
'Field' shall mean the use of immunoassays for diagnostic purposes to quantitate hemoglobin type A1c.

IPSCIO Record ID: 1800

License Grant
The University grants to IMMTECH a worldwide, exclusive, and non-assignable License to use the Invention and Patent Rights (07/765,169 ) of Immunoassay for Identifying Alcoholics and Monitoring Alcohol Consumption (NIT 9134); Licensed Product coveted hereby and to make, have made, use and sell the products in the Field of Quantitative Diagnostics.  Quantitative Diagnostics shall mean the use of immunoassays that yield a quantitative answer and are generally performed via enzyme-linked antibody methodology.
Field of Use
Field of Use  shall mean the exclusive use of the invention and patent rights for quantitative diagnostics.

IPSCIO Record ID: 2557

License Grant
The Licensee was granted exclusive, worldwide rights under the Licensed Patents and under the Licensed Technology to possess, use, make, have made, lease, sell and have sold all Materials, Progeny, Biomaterials, Technology, Improvements thereto, and Licensed Products.
License Property
Licensed Patents shall include U.S. Patent No. 5,484,735 to  Davis et al. filed November 12, 1993 and entitled Immunoassay of Glycosylated Proteins Employing Antibody to Reductive Glycosylated N-Terminal Amino Acids (hereinafter referred to as the 735 Patent).
Field of Use
Licensee desires to develop commercial diagnostic assays for determining hemoglobin in type Alc (Hb(Alc)) by detecting a reduced form of Hb(Alc).  Licensee desires to grow such cell lines and harvest monoclonal antibodies from said cell lines for the purpose of evaluating the suitability of the same for a commercial Hb(Alc) assay and for the purpose of evaluating whether to exercise an option to license the exclusive, worldwide rights associated with such cell lines, such monoclonal antibodies and such related information known to the Licensor.

IPSCIO Record ID: 2119

License Grant
Under two license agreements, the Company has been granted the right and license throughout the world to use Licensor’s magnetocluster technology in connection with RaPID Assay products.  These agreements grant the right to develop, manufacture, market and sell products embodying Licensor-developed methods and techniques, for the production of magnetically separable particles used for the detection of environmental analytes.
License Property
The RaPID Assay product line for detection of pesticides and toxic organic contaminants employs magnetic particle immunoassay technology for highly precise determination of very low concentrations of contaminants.  Magnetic particle assays have a greater number of steps and require more technical expertise to execute than latex filtration assays, but are more suited to processing of larger number of samples at a single time, can be highly quantitative, and are relatively inexpensive on a cost-per-test basis.  These characteristics make magnetic particle immunoassays effective measurement tools in both laboratory and certain field applications, especially where highly precise results are required.
Field of Use
Licensee develops and sells on-site test systems, based primarily on immunoassay technology, designed for fast and inexpensive detection of contaminants in soil and water and other media samples relating to environmental remediation and environmental monitoring purposes.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.